Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982199 · ClinicalTrials.gov registry record · Phase 2
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
A Phase 2 study, sponsored by Janssen Vaccines & Prevention B.V..
- Terminated
- Registry status
- Phase 2
- Development phase
- 5,815
- Enrollment target
NCT03982199 is a Phase 2 study that was terminated before completion, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 5,815 participants.
The verdict
NCT03982199, a Phase 2 study, was terminated before completion, sponsored by Janssen Vaccines & Prevention B.V..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5,815 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory tract disease (LRTD), when compared to placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,815 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982199
The ClinicalTrials.gov registry entry for NCT03982199 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5,815 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03982199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03982199 about?
NCT03982199 is a clinical study titled "A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older". The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory tract disease (LRTD), when compared to placebo.
What is the current status of trial NCT03982199?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5,815 participants. The study started on 2019-08-01. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT03982199?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03982199?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.